High loading dose AmBisome is efficacious and well tolerated in the management of invasive fungal infection in hematology patients.
Despite improved supportive care, and the introduction of less toxic lipid-formulations of amphotericin B deoxycholate and other new antifungal agents the mortality from invasive fungal infection (IFI) in hematology patients remains high. New management strategies are therefore required to improve outcome.
McLintock
Lorna A
LA
Cook
Gordon
G
Holyoake
Tessa L
TL
Jones
Brian L
BL
Kinsey
Sally E
SE
Jackson
Graham H
GH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D007674:Kidney Diseases / Q000139:chemically induced; D008081:Liposomes / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome
D000935:Antifungal Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B